Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, discusses the highlights from the World Sleep Conference 2022. Dr Garcia-Borreguero states that new clinical trials and drugs in the field of insomnia is of most interest; orexin antagonists demonstrate much potential and have a very different mode of action from previous drugs. This is the first time in Europe where the field of insomnia is seeing long-term, large trials for lemborexant and daridorexant – producing impressive results. These agents have the potential to change the way patients with insomnia are treated. With adverse side effects and low efficacy with mid to long-term administration of previous drugs like benzodiazepines, it is important to have new drugs with new modes of action in treating insomnia. This interview took place at the World Sleep Conference in Rome, Italy.